Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


21 11, 2013

Staggering amount of myeloma related data to be revealed at this year’s ASH (Part Two)

Tags: , , , , , , |5 Comments

I promised more information about the upcoming American Society of Hematology (ASH) meetings in New Orleans; specifically data from promising clinical trials and laboratory studies that will be presented there.  Last week I ran these posts: Staggering amount of myeloma related data to be revealed at this year’s ASH (Part One)   Innovative genetic diagnostics

25 05, 2013

Mayo Clinic’s willingness to consider delaying SCT grabs reader attention

Tags: , , , , |10 Comments

As lead writer, editor, layout stumbler and bumbler here at MMB, I am continually wondering:  What makes one post more popular than another?  Let's examine one of my most read posts of all time to see why over 3700 people read it last month. The post itself is simple enough; a composite of several different

5 04, 2013

Mayo Clinic and delaying stem cell transplants, sequester cuts hurt cancer patients and perifosine scrapped

Tags: , , , |22 Comments

Too much myeloma related news to run a Fun Friday! post today.  Here are a the most important developments from the past week: I received a half dozen emails about Mayo Clinic's new multiple myeloma patient guidelines.  Not a lot new there.  Dr. Rajkumar stressed the importance of using gene profiling to break patients into

7 05, 2012

BREAKING NEWS: Perifosine Stage 3 trial will proceed!

Tags: , |2 Comments

When perifosine failed to extend overall survival (OS) in patients with metastasized colorectal cancer recently in a Stage 3 trial, company officials and financial analysts speculated that plans to start a stage 3 multiple myeloma theory might be scrapped: Ouch!  Will financial difficulties stop promising anti-myeloma therapy? More about perifosine's uncertain future I'm pleased to

4 04, 2012

More about perifosine’s uncertain future

Tags: , , |1 Comment

Monday I shared the disappointing news about how the promising anti-myeloma drug, perifosine, might not ever make it to market. Here are excerpts from a more measured, detailed look at what may happen now that perifosine failed to extend the lives of patients with advanced colon cancer from an online newsletter used by serious investors,

29 12, 2011

Dr. Paul Richardson reviews encouraging trial results from ASH

Tags: , , , , , , |2 Comments

Medscape Today has released an excellent written and video review of multiple myeloma-related news from ASH. Dr. Paul Richardson, well known myeloma specialist with Dana-Farber in Boston, kicks things off by reviewing results from several exciting new, experimental drugs that his research group are studying. MLN9708, an oral proteasome inhibitor, and marizomib, a particularly potent

11 12, 2011

Full coverage of Friday evening IMF Satellite Symposium event (Part Three)

Tags: , , , , , , , , , , , , |1 Comment

I know, I know.  I'm falling behind!  I'm so busy collecting and analyzing newly released myeloma related research data, I have barely had time to write. Here is the final installment of my three part report about the IMF's Friday evening Satellite Symposium. I saved the best for last!  Dr. Robert Orlowski with M.D. Anderson

9 06, 2011

ASCO Odds/Ends And Clinical Study Links

Tags: , , , , , , , , , , |0 Comments

A few more quick notes from ASCO before the first of a long running series about ways to improve peripheral neuropathy (PN) starts later today: Secondary Cancer Risk From Using Revlimid: Based on the results of this retrospective analysis, Dr. Palumbo concluded that Revlimid ,when used with melphalan, increases the rate of secondary cancers.  The

18 04, 2011

Every Multiple Myeloma Patient Or Caregiver Should Read Friday’s Myeloma Beacon Feature About Emerging Myeloma Therapies

Tags: , , , , , , , , |2 Comments

The Myeloma Beacon ran an excellent review of new anti-myeloma therapies which are in late stages of development:  Promising New Drugs For Myeloma: Will The Future Come Soon Enough?The article is written by Dr. S. Vincent Rajkumar with Mayo Clinic.  I was going to reference it over the weekend, but forgot about it until I

29 03, 2011

Find News About Upcomming American Association For Cancer Research on

Tags: , , |0 Comments

We are entering another busy multiple myeloma related news cycle as we approach the American Association for Cancer Research, which will be held at the Orange County Convention Center in Orlando, Florida, from April 2-6, 2011.Check-out to access articles about the new bone strengthening and anti-myeloma drug, bafetinib, Geraldine Ferraro's funeral details and the

8 11, 2010

More from Dr. Stewart About Treatment and Clinical Study Options For Multiple Myeloma Patients Who Have Become Resistant To Revlimid And/Or Velcade Therapy

Tags: , , , , , , , , , , , |0 Comments

Yesterday I shared Dr. Stewart's hopeful message to patients for whom Revlimid and Velcade no longer work.  Here is his response to the question: Should I consider a clinical trial? What new therapies in clinical trials look promising?  as posted on the Multiple Myeloma Research Foundation (MMRF) site recently:Clinical trials are an important option for patients who

20 07, 2010

Even The Associated Press Makes Mistakes!

Tags: , , |0 Comments

Thursday I quoted the Associated Press (AP) in a story I did about a new anti-myeloma drug, perifosine.  You would have had to read it very carefully, but AP is admiting it made a mistake which is good news for multiple myeloma patients.  NEW YORK   Correction: Keryx's perifosine drug storyIn a story July 14 about Keryx Biopharmaceuticals, The Associated

15 07, 2010

Perifosine Continues To Show Strong Anti-Cancer Results: Multiple Myeloma Perifosine Update

Tags: , , , |0 Comments

Keryx's perifosine gets second orphan drug status(AP) – 10 hours agoNEW YORK — Keryx Biopharmaceuticals Inc. said Wednesday that its experimental cancer drug perifosine received orphan drug status as a treatment for neuroblastoma, a cancer that affects the nervous system and mostly strikes young children...Perifosine also has orphan drug status as a colorectal cancer treatment,

9 07, 2010

Anti-Myeloma Drug, Perifosine, May Also Work Against Colon Cancer

Tags: , , , , , |0 Comments

Interesting news I wanted to share about one of several new anti-myeloma therapy agents, perifosine.  Currently in Phase 3 trials in combination with Velcade, perifosine apparently has anti-cancer properties which go far beyond multiple myeloma:  Aeterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Trial with Perifosine in Colorectal CancerThe

21 12, 2009

Details About New Anti-Myeloma Drug, Perifosine

Tags: , , , , |0 Comments

Here is a clinical summary about the new myeloma drug I wrote about last night, perifosine, from a Website named ""KRX-0401 (perifosine) is a potential oral anti-cancer agent that suppresses the pathways associated with the programmed growth, death, differentiation and survival of cells. Developed by Keryx, the drug is most effective in modulating Akt, as

21 12, 2009

Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma

Tags: , , , , |0 Comments

Here is info about a newly organized Phase 3 study combining perifosine with Velcade:NEW YORK, Dec 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial,

3 12, 2009

Perifosine Approved For FDA Fast Track

Tags: , |0 Comments

I get a lot of my drug related news from business Websites. Here is an article I read today on RTT News about a new myeloma drug, perifosine:RTTNews) - Keryx Biopharmaceuticals Inc. (KERX: News ) Wednesday said the FDA has granted Fast Track designation for its KRX-0401 or perifosine indicated in the treatment of relapsed/refractory

7 08, 2009

Perifosine Approved For Phase III Trial

Tags: , , , , , , |0 Comments

Found this article about new anti-cancer drug on U.S. Food and Drug Administration has announced approval for a Phase 3 clinical trial evaluating perifosine in relapsed and refractory multiple myeloma patients. Perifosine, also known as KRX-0401, is an oral anti-cancer agent produced by Aeterna Zentaris and licensed in the U.S., Canada, and Mexico by